Navigation Links
Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
Date:8/25/2011

CHAPEL HILL, N.C., Aug. 25, 2011 /PRNewswire/ -- The global generics drug market has grown to $120 billion and with a number of blockbusters set to go off patent, the sector will see even more growth in the coming years. But as organizations involved in generics ramp up their manufacturing efforts, success hinges on the critical bioequivalence studies that are required to bring new generic drugs to market.

Best Practices, LLC conducted a wide-ranging and detailed study to help generics manufacturers identify effective strategies and processes for managing the bioequivalence component of generics development, where quality, cost and speed are all vital success factors. This benchmarking study aims to identify key cost, quality and productivity metrics for the process of conducting bioequivalence studies.

"Pharma Bioequivalence Strategies: Performance Metrics, Processes & Trends" is a new 49-page report that delivers key performance and process benchmarks that generics manufacturers can use to evaluate their own programs and costs. Beyond key benchmarks that drive bioequivalence studies such as studies per ANDA, cost per volunteer, cost per sample, the research study provides a clear picture of organizations' use of outsourcing for bioequivalence (BE) studies. In all, the report identifies:         

  • Key industry metrics for bioequivalence program costs 
  • Geographic trends in bioequivalence testing 
  • Sponsor support activities that drive bioequivalence success 
  • Successful QA structures and strategies in bioequivalence 
  • Trends in use of pilot studies, power and e-submissions  

Go to http://www3.best-in-class.com/rr1109.htm to review a complimentary summary with samples of metrics such as use of CROs for BE studies in emerging markets, percentage of organizations with quality assurance groups and benefits for use of pilot studies. The study includes insights drawn from primary research involving 20 executives at 18 leading generic pharmaceutical manufacturing companies.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vivo Ventures Announces Promotions of Dr. Chen Yu and Dr. James Zhao to Managing Partner
2. Elekta to Demonstrate Advanced Solutions for Managing Cancer Safely and Effectively at ESTRO 2011
3. CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste
4. ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S.
5. 2P2D Ltd. Announces the Appointment of Tovi Bachar, Former Managing Director of GE Healthcare Israel, as Director and Chairman
6. DNA Direct Announces New Health Plan Clients Managing Molecular Diagnostic and Genetic Tests
7. States, Federal Government Could Save $30 Billion by Managing Medicaid Pharmacy More Like Medicare and Commercial Sector Programs
8. Point-of-Care Partners Recognized for Role in Managing SEMI
9. Skytron Highlights RFID-RTLS Cost Saving Solutions in the OR at Managing Todays OR Suite Conference
10. Elsevier Appoints Suzanne BeDell as Managing Director, Science and Technology (S&T) Books
11. Elsevier Appoints Martin OMalley as Managing Director of New Global Sales Group in Science & Technology Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Glenmark Pharmaceuticals, a global pharmaceutical company, today ... fixed-dose combination of mometasone furoate (25 mcg) and ... nasal spray being studied for the treatment of ... recently completed Phase 3 trial assessing the efficacy ... mometasone, olopatadine or placebo. "We continue ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 2.87% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... ... 29, 2017 , ... The assembly of synthetic DNA has ... repetitive steps and often scientists require many different versions of DNA. Therefore, this ... in a lower error rate and cost saving for reagents and consumables. , ...
(Date:3/29/2017)... North Hollywood, CA (PRWEB) , ... March 29, 2017 , ... ... and Northridge , is now offering laser dental treatments. Dental lasers are safe ... treatments. Laser dentistry expands patients’ options and can improve the overall quality of care. ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage ... Intercontinental Time Square, New York. , The program will be led by ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, ... in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is ... Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in ...
Breaking Medicine News(10 mins):